This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dell’Italia, L. J. Articles by Oparil, S. Search for Related Content PubMed PubMed Citation Articles by Dell’Italia, L. J. Articles by Oparil, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy

(Circulation. 1999;100:2305.)
© 1999 American Heart Association, Inc.

Editorials

Bradykinin in the Heart

Friend Or Foe?

Louis J. Dell’Italia, MD; Suzanne Oparil, MD

From the University of Alabama, Department of Medicine, Vascular Biology and Hypertension Program, Division of Cardiovascular Disease and the Birmingham Veterans Affairs Medical Center, University Station, Birmingham, Ala.

Key Words: Editorials • bradykinin • angiotensin • myocardium • heart failure • hypertension

Hypertension and heart failure are marked by activation of both the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. These forms of neurohumoral activation, in turn, have deleterious effects on the heart, kidney, and other target organs, worsening the prognosis in these disease states. Pharmacological agents that interrupt the RAAS are useful in both improving hemodynamics and preventing morbidity and mortality in such patients. In particular, treatment with ACE inhibitors has been shown to improve survival in patients with advanced heart failure and after myocardial infarction. It is hypothesized that ACE inhibitors exert beneficial effects by inhibiting both circulating and cardiac tissue ACE, thus attenuating unfavorable remodeling of the left ventricle (LV), reducing afterload, and improving the balance between thrombotic and thrombolytic factors. It remains unclear whether the dominant mechanism of action of ACE inhibitors in the setting of LV dysfunction relates to their global hemodynamic effects (which result in improved loading conditions), to reduced production of angiotensin (Ang) II with subsequent diminished Ang II type 1 (AT₁) receptor activation, or to alteration of other neurohormonal systems, such as the kallikrein-kinin system.

Importantly, in addition to generating Ang II from Ang I, ACE catalyzes the degradation of bradykinin (BK) to inactive metabolites.¹ Studies of recombinant full-length ACE have shown that the apparent K_m of ACE for BK is substantially lower than for Ang I, which indicates more favorable kinetics for hydrolysis of BK than for conversion of Ang I to Ang II.² Furthermore, site-directed mutagenesis demonstrated that the K_m . . . [Full Text of this Article]

This article has been cited by other articles:

				H. S. Lim, R. J. MacFadyen, and G. Y. H. Lip Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart Arch Intern Med, September 13, 2004; 164(16): 1737 - 1748. [Abstract] [Full Text] [PDF]

				Y. Oishi, R. Ozono, Y. Yano, Y. Teranishi, M. Akishita, M. Horiuchi, T. Oshima, and M. Kambe Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling Hypertension, March 1, 2003; 41(3): 814 - 818. [Abstract] [Full Text] [PDF]

				T. Scholze, E. Moskvina, M. Mayer, H. Just, H. Kubista, and S. Boehm Sympathoexcitation by Bradykinin Involves Ca2+-Independent Protein Kinase C J. Neurosci., July 15, 2002; 22(14): 5823 - 5832. [Abstract] [Full Text] [PDF]

				C.-C. Wei, C. M. Ferrario, K. B. Brosnihan, D. M. Farrell, W. E. Bradley, A. A. Jaffa, and L. J. Dell'Italia Angiotensin Peptides Modulate Bradykinin Levels in the Interstitium of the Dog Heart in Vivo J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 324 - 329. [Abstract] [Full Text] [PDF]

				M. M. Multani, R. S. Krombach, A. T. Goldberg, M. K. King, J. W. Hendrick, J. A. Sample, S. C. Baicu, C. Joffs, M. deGasparo, and F. G. Spinale Myocardial Bradykinin Following Acute Angiotensin-Converting Enzyme Inhibition, AT1 Receptor Blockade, or Combined Inhibition in Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 369 - 376. [Abstract] [PDF]

				M. Schachter ACE inhibitors, angiotensin receptor antagonists and bradykinin Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1): 27 - 29. [PDF]

				X.-P. Yang, Y.-H. Liu, D. Mehta, M. A. Cavasin, E. Shesely, J. Xu, F. Liu, and O. A. Carretero Diminished Cardioprotective Response to Inhibition of Angiotensin-Converting Enzyme and Angiotensin II Type 1 Receptor in B2 Kinin Receptor Gene Knockout Mice Circ. Res., May 25, 2001; 88(10): 1072 - 1079. [Abstract] [Full Text] [PDF]